Select Publications
Conference Papers
, 2012, 'Identification of Thymosin-beta-4-X as Indicator for Cytopathic Responses of Fenretinide and Vorinostat Combination Treatment', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, Barcelona, pp. S187 - S187, presented at 22nd Biennial Congress of the European-Association-for-Cancer-Research, SPAIN, Barcelona, 07 July 2012 - 10 July 2012, http://dx.doi.org/10.1016/S0959-8049(12)71421-1
, 2009, 'Perinatal Myc signalling as a mechanism of embryonal cancer initiation', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702603052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2008, 'STABILIZATION OF THE MYCN ONCOPROTEIN AS A MECHANISM OF INITIATION AND PROGRESSION IN MEDULLOBLASTOMA RESULTING FROM SONIC HEDGEHOG PATHWAY ACTIVATION', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, NV, Las Vegas, pp. 870 - 870, presented at 13th Annual Meeting of the Society-for-Neuro-Oncology (SNO), NV, Las Vegas, 20 November 2008 - 23 November 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259854500409&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2008, 'The role of the estrogen-responsive B box protein (EBBP) in cancer cell cycle progression', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, FRANCE, Lyon, pp. 95 - 95, presented at 20th Meeting of the European-Association-for-Cancer-Research, FRANCE, Lyon, 05 July 2008 - 08 July 2008, http://dx.doi.org/10.1016/S1359-6349(08)71542-8
, 2006, 'Characterization of a novel regulator of the retinoid signal: The estrogen-responsive B box protein.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454608804357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2006, 'Neuroblastoma tumor initiation: MYCN mediated mechanisms of resistance to cell death', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454606201380&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Conference Posters
, 2025, 'The super enhancer-driven long noncoding RNA lncNB promotes neuroblastoma tumorigenesis by interacting with MSI2 protein and is targetable by small molecule compounds', IL, Chicago, Vol. 85, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 25 April 2025 - 30 April 2025, http://dx.doi.org/10.1158/1538-7445.AM2025-2608
, 2022, 'Abstract 6298: The novel long noncoding RNA lncNeur promotes neuroblastoma by up-regulating AURKA and Myc expression', Vol. 82, pp. 6298 - 6298, http://dx.doi.org/10.1158/1538-7445.am2022-6298
Conference Presentations
, 2014, 'TRIM16 inhibits cell growth through direct interaction and modulation of TDP43 protein stability in cancer cells', presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-1403
Conference Abstracts
, 2025, 'The role of the RNA methyltransferase RNAMT1 as a tumorigenic driver and therapeutic target in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 85, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 25 April 2025 - 30 April 2025, http://dx.doi.org/10.1158/1538-7445.AM2025-2613
, 2019, 'Single-Cell RNA-SEQ Identifies that Adrenergic Neuroblasts Possess a BI-FATE Differentiation Potential in Peripheral Neuroblastictumors', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S345 - S346, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458004050&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3659
, 2015, 'MYCN TRANSCRIPTIONALLY REPRESSES CD9 TO TRIGGER AN INVASION-METASTASIS CASCADE IN NEUROBLASTOMA', in PEDIATRIC BLOOD & CANCER, WILEY-BLACKWELL, Vol. 62, pp. S150 - S150, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361247200022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-146
Preprints
, 2020, Single-cell RNA-sequencing of peripheral neuroblastic tumors reveals an aggressive transitional cell state at the junction of an adrenergic-mesenchymal transdifferentiation trajectory, http://dx.doi.org/10.1101/2020.05.15.097469
, Pyrimido[1,2-A]Benzimidazoles as Inhibitors of Oncoproteins Ubiquitin Specific Protease 5 and MYCN in the Childhood Cancer Neuroblastoma, http://dx.doi.org/10.2139/ssrn.4283384
Other
, 2023, Data from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.c.6530307.v1
, 2023, Data from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.c.6530307
, 2023, Supplementary Figure S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479852
, 2023, Supplementary Figure S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479852.v1
, 2023, Supplementary Figure S2 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479849.v1
, 2023, Supplementary Figure S2 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479849
, 2023, Supplementary Figure S3 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479846.v1
, 2023, Supplementary Figure S3 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479846
, 2023, Supplementary Figure S4 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479843
, 2023, Supplementary Figure S4 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479843.v1
, 2023, Supplementary Figure S5 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479840.v1
, 2023, Supplementary Figure S5 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479840
, 2023, Supplementary Figure S6 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479837.v1
, 2023, Supplementary Figure S6 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479837
, 2023, Supplementary Figure S7 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479834
, 2023, Supplementary Figure S7 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479834.v1
, 2023, Supplementary Materials & Methods from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479831
, 2023, Supplementary Materials & Methods from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479831.v1
, 2023, Supplementary Table S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479828
, 2023, Supplementary Table S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy, http://dx.doi.org/10.1158/1078-0432.22479828.v1